NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
PLX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX is valued quite cheap, while showing a decent growth score. This is a good combination! This makes PLX very considerable for value investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 3.99% | ||
ROE | 6.79% | ||
ROIC | 6.87% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 7.34% | ||
PM (TTM) | 5.49% | ||
GM | 54.46% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | -1.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.34 | ||
Quick Ratio | 1.52 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 85 | ||
Fwd PE | 8.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 26.92 | ||
EV/EBITDA | 35.22 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.55
-0.06 (-2.3%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 85 | ||
Fwd PE | 8.14 | ||
P/S | 3.73 | ||
P/FCF | 26.92 | ||
P/OCF | 22.94 | ||
P/B | 4.6 | ||
P/tB | 4.6 | ||
EV/EBITDA | 35.22 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 3.99% | ||
ROE | 6.79% | ||
ROCE | 8.2% | ||
ROIC | 6.87% | ||
ROICexc | 11.71% | ||
ROICexgc | 11.71% | ||
OM | 7.34% | ||
PM (TTM) | 5.49% | ||
GM | 54.46% | ||
FCFM | 13.84% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 98.31% | ||
Cap/Sales | 2.4% | ||
Interest Coverage | 2.56 | ||
Cash Conversion | 166.14% | ||
Profit Quality | 252.12% | ||
Current Ratio | 2.34 | ||
Quick Ratio | 1.52 | ||
Altman-Z | -1.7 |